GLP-1 Drugs Quietly Reshape How Americans Shop for Food, Study Finds
This article first appeared on GuruFocus. Weight loss may be just one side effect of GLP-1 drugs. A…
Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
This article first appeared on GuruFocus. Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical…
US approves Wegovy pill, giving Novo Nordisk an edge in obesity drug competition
US regulators have given the green light to a pill version of the blockbuster weight-loss drug Wegovy, the…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
1 Healthcare Giant Set to Soar in 2026
Novo Nordisk cut its guidance and changed its CEO this past year. Amid the troubling developments, the stock…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
High-Dose Wegovy Takes Aim at Lilly’s Zepbound
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) said its high-dose version of Wegovy has received a…
Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks – National
Negotiations that could have led to coverage of weight-loss drug Wegovy under Canadian public health plans are not…
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer’s trials
By Deena Beasley SAN DIEGO Dec 2 (Reuters) – Novo Nordisk in 2020 launched pivotal trials of its…
Weight-Loss Drug Zepbound Cost Drops To $299 A Month After Trump Deal
Topline Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo…
Weight loss drugs are rewriting the global business of how we eat
A US pharmaceutical company went to a $1.5 trillion valuation last week, joining a club that up until…